Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Income from Continuing Operations (2016 - 2023)

Rapid Therapeutic Science Laboratories' Income from Continuing Operations history spans 8 years, with the latest figure at 46422.0 for Q2 2023.

  • For Q2 2023, Income from Continuing Operations rose 226.02% year-over-year to 46422.0; the TTM value through Jun 2023 reached 59556.0, up 101.74%, while the annual FY2022 figure was 1794726.0, 37.42% up from the prior year.
  • Income from Continuing Operations for Q2 2023 was 46422.0 at Rapid Therapeutic Science Laboratories, down from 191271.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 191271.0 in Q1 2023 and bottomed at 1579751.0 in Q1 2022.
  • The 5-year median for Income from Continuing Operations is 311148.0 (2020), against an average of 471084.73.
  • The largest annual shift saw Income from Continuing Operations crashed 719.97% in 2020 before it skyrocketed 226.02% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 176690.0 in 2019, then crashed by 759.17% to 1518064.0 in 2020, then grew by 19.98% to 1214807.0 in 2021, then skyrocketed by 104.03% to 48939.0 in 2022, then dropped by 5.14% to 46422.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Income from Continuing Operations are 46422.0 (Q2 2023), 191271.0 (Q1 2023), and 48939.0 (Q4 2022).